BlackRock Advisors’s Acorda Therapeutics ACOR Stock Holding History

BlackRock Advisors’s Portfolio ACOR Stock Details ACOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$1.12M	Sell	498 -43	-8%	-$102K	﹤0.01%	1799
2016 Q3	$1.35M	Buy	541 +13	+2%	+$38.8K	﹤0.01%	1657
2016 Q2	$1.62M	Sell	528 -280	-35%	-$911K	﹤0.01%	1535
2016 Q1	$2.56M	Buy	808 +89	+12%	+$369K	﹤0.01%	1320
2015 Q4	$3.69M	Sell	719 -218	-23%	-$953K	﹤0.01%	1195
2015 Q3	$2.98M	Buy	937 +17	+2%	+$65.9K	﹤0.01%	1246
2015 Q2	$3.68M	Sell	920 -219	-19%	-$846K	﹤0.01%	1075
2015 Q1	$4.55M	Sell	1,139 -1,801	-61%	-$8.25M	﹤0.01%	996
2014 Q4	$14.4M	Sell	2,940 -30	-1%	-$129K	0.01%	670
2014 Q3	$12.1M	Sell	2,970 -1,638	-36%	-$6.14M	0.01%	726
2014 Q2	$18.6M	Sell	4,608 -1,252	-21%	-$5.11M	0.02%	581
2014 Q1	$26.7M	Buy	5,860 +609	+12%	+$2.46M	0.03%	491
2013 Q4	$18.4M	Sell	5,251 -3,356	-39%	-$13.1M	0.02%	577
2013 Q3	$35.3M	Sell	8,607 -1,149	-12%	-$4.95M	0.04%	408
2013 Q2	$38.6M	Buy	+9,756	New	+$40.2M	0.04%	364

Other funds holding ACOR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

BlackRock Advisors's ACOR Position: Q4 2016 in Review

BlackRock Advisors reduced its Acorda Therapeutics (ACOR) stake by 7.9% in Q4 2016, selling an estimated $102K and leaving 498 shares worth $1.12M. The position accounts for ﹤0.01% of the portfolio, ranked #1799.

BlackRock Advisors first reported a position in ACOR in Q2 2013 and has held it in 15 quarters since. The position peaked at $38.6M in Q2 2013. 175 funds tracked by Wall St. Rank hold ACOR as of Q4 2016.

BlackRock Advisors held 498 shares of Acorda Therapeutics worth $1.12M as of Q4 2016.
BlackRock Advisors sold 43 Acorda Therapeutics shares in Q4 2016, an estimated $102K.
Acorda Therapeutics made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #1799 holding.
BlackRock Advisors first reported a position in Acorda Therapeutics in Q2 2013 and has held it in 15 quarters since.
BlackRock Advisors's Acorda Therapeutics position peaked at $38.6M in Q2 2013.
175 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.